Summary
Global Markets Direct’s, ‘Vitiligo - Pipeline Review, H1 2016’, provides an overview of the Vitiligo pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Vitiligo, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vitiligo and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Vitiligo
- The report reviews pipeline therapeutics for Vitiligo by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Vitiligo therapeutics and enlists all their major and minor projects
- The report assesses Vitiligo therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Vitiligo
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Vitiligo
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vitiligo pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Ache Laboratorios Farmaceuticos S/A
Biocon Limited
Bristol-Myers Squibb Company
Clinuvel Pharmaceuticals Limited
Sun Pharma Advanced Research Company Ltd.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vitiligo Overview 6
Therapeutics Development 7
Pipeline Products for Vitiligo - Overview 7
Pipeline Products for Vitiligo - Comparative Analysis 8
Vitiligo - Therapeutics under Development by Companies 9
Vitiligo - Therapeutics under Investigation by Universities/Institutes 11
Vitiligo - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Vitiligo - Products under Development by Companies 14
Vitiligo - Products under Investigation by Universities/Institutes 15
Vitiligo - Companies Involved in Therapeutics Development 16
Ache Laboratorios Farmaceuticos S/A 16
Biocon Limited 17
Bristol-Myers Squibb Company 18
Clinuvel Pharmaceuticals Limited 19
Sun Pharma Advanced Research Company Ltd. 20
Vitiligo - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
abatacept - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ACH-24 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
afamelanotide - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Gene Therapy to Activate SOX9 for Vitiligo and Melanoma - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
itolizumab - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
SUN-0597 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
VLRX-001 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Vitiligo - Recent Pipeline Updates 44
Vitiligo - Dormant Projects 53
Vitiligo - Product Development Milestones 54
Featured News & Press Releases 54
Dec 03, 2015: Positive preliminary results in Singaporean vitiligo study 54
Dec 03, 2015: Update on North American vitiligo program for SCENESSE 55
May 05, 2015: Clinuvel announces innovative melanocortin for new indications 56
Mar 20, 2015: SCENESSE vitiligo data presented at world’s largest dermatology conference 57
Sep 19, 2014: SCENESSE vitiligo study results published in JAMA Dermatology 58
May 06, 2014: Clinuvel’s Phase II vitiligo study commences in Singapore 59
Mar 20, 2014: SCENESSE data to feature at American Academy of Dermatology 59
Nov 04, 2013: Clinuvel to start a Phase II vitiligo study in Singapore 60
Sep 02, 2013: Five month study follow up shows SCENESSE combination treatment provided stable repigmentation in vitiligo patients 61
Mar 01, 2013: SCENESSE data to be presented at American Academy of Dermatology, San Gallicano Rare Disease conference 62
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64
List of Tables
Number of Products under Development for Vitiligo, H1 2016 7
Number of Products under Development for Vitiligo - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Vitiligo - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2016 16
Vitiligo - Pipeline by Biocon Limited, H1 2016 17
Vitiligo - Pipeline by Bristol-Myers Squibb Company, H1 2016 18
Vitiligo - Pipeline by Clinuvel Pharmaceuticals Limited, H1 2016 19
Vitiligo - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 20
Assessment by Monotherapy Products, H1 2016 21
Number of Products by Stage and Target, H1 2016 23
Number of Products by Stage and Mechanism of Action, H1 2016 25
Number of Products by Stage and Route of Administration, H1 2016 27
Number of Products by Stage and Molecule Type, H1 2016 29
Vitiligo Therapeutics - Recent Pipeline Updates, H1 2016 44
Vitiligo - Dormant Projects, H1 2016 53
List of Figures
Number of Products under Development for Vitiligo, H1 2016 7
Number of Products under Development for Vitiligo - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 21
Number of Products by Targets, H1 2016 22
Number of Products by Stage and Targets, H1 2016 22
Number of Products by Mechanism of Actions, H1 2016 24
Number of Products by Stage and Mechanism of Actions, H1 2016 24
Number of Products by Routes of Administration, H1 2016 26
Number of Products by Stage and Routes of Administration, H1 2016 26
Number of Products by Molecule Types, H1 2016 28
Number of Products by Stage and Molecule Types, H1 2016 28
